Slide 1: Seqirus Presentation at 2019 Macquarie Equities Conference
For personal use only Seqirus Presentation at 2019 Macquarie Equities Conference Please find attached the Seqirus presentation at the 2019 Macquarie Equities Conference. For further information, please contact: Investors: Media: Mark Dehring Christina Hickie VP Investor Relations Senior Manager, Com
Slide 2: Seqirus Macquarie Australia Conference
For personal use only SEQIRUS MACQUARIE AUSTRALIA CONFERENCE Gordon Naylor, President JOURNAL April 2019 October 2018 2 | ON THE FRONT LINE
Slide 3: Legal Notice: Forward looking statements
LEGAL NOTICE For personal use only Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and produ
Slide 4: Burden of influenza is significantly greater than any other infectious disease
BURDEN OF INFLUENZA IS SIGNIFICANTLY GREATER THAN ANY OTHER INFECTIOUS DISEASE For personal use only INFLUENZA Source: Cassini et al, Impact of infectious diseases on population health, European Union and European Economic Area countries, 2009 to 2013. Eurosurveillance, April 2018. 4 | ON THE FRON
Slide 5: Influenza poses a constant pandemic threat
INFLUENZA POSES A CONSTANT PANDEMIC THREAT For personal use only PANDEMIC INCIDENCE AND MORTALITY 4 influenza pandemics in last century 50m+ 2m 1m 0.3m Next pandemic is a question of ‘when’ not ‘if’ Hong Kong Flu Spanish Flu Swine Flu Asian Flu (H1N1) (H2N2) (H3N2) (H1N1) Current concerns around H7N
Slide 6: Global scale with industry-leading innovation
GLOBAL SCALE WITH INDUSTRY-LEADING INNOVATION For personal use only Seqirus is one of the world’s Major pandemic partner to largest influenza vaccine governments around the world manufacturers with innovative technologies and products Differentiated influenza vaccines based on egg- and cell- Broades
Slide 7: Seqirus influenza vaccines
SEQIRUS INFLUENZA VACCINES For personal use only HIGH-RISK STANDARD RISK POPULATIONS SEASONAL ADJUVANTED TIV / QIV SEASONAL TIV / QIV PANDEMIC EGG BASED CELL BASED INFLUENZA SCIENCE 7 | ON THE FRONT LINE
Slide 8: Key milestones: delivering the turnaround
KEY MILESTONES DELIVERING THE TURNAROUND For personal use only • Transaction close: 31 July 2015 Revenue REVENUE AND EBIT (US$M) • Management team and Global HQ FY16 EBIT • Commenced integration • TIV portfolio 1,088 • Launch of QIV and FLUAD® in US 900 • Growth in pandemic reservation fees FY17 731
Slide 9: 1H FY19 revenue
1H FY19 REVENUE For personal use only CATEGORY REGION US $M +53% 1000 +21%1 EUROPE 14% 800 ASIA PAC -11% 600 10% OTHER FLUAD NORTH US$949M 400 AMERICA ROW 5% TRIVALENT 71% +21% +2% QUADRIVALENT 200 PANDEMIC 0 1H18 1H19 +22% GROWTH IN QIV & FLUAD 1. Growth percentages shown at constant currency to re
Slide 10: Industrialisation of cell-based manufacturing
INDUSTRIALISATION OF CELL-BASED MANUFACTURING For personal use only VOLUMES OF FLUCELVAX® MANUFACTURED BY CALENDAR YEAR Process improvements 30 25 Cell-specific seeds MILLION DOSES 20 FCC 3.0 (new process) 15 approved in 2018 10 5 Expansion of warehouse 0 and fill & finish CY14 CY15 CY16 CY17 CY18 T
Slide 11: Real world effectiveness of cell-based influenza vaccines
A NOTE ON REAL WORLD EFFECTIVENESS OF TERMINOLOGY CELL-BASED INFLUENZA VACCINES For personal use only Randomised clinical trials provide • Relative vaccine effectiveness of cell vs egg-based an estimate of efficacy in a vaccines in 2017/18 US Season controlled setting in a well-defined population •
Slide 12: Recent developments
RECENT DEVELOPMENTS For personal use only SEASONAL INFLUENZA PANDEMIC AUST/NZ COMMERCIAL INFLUENZA • FLUCELVAX® - all strains manufactured • Strong performance from using cell-specific seed for 2019/20 season • Reservation Gardasil and pain franchise agreements with the • Preferential recommendation
Slide 13: Looking ahead: key growth drivers over the next decade
LOOKING AHEAD – KEY GROWTH DRIVERS OVER THE NEXT DECADE For personal use only COMMERCIAL KEY MARKETS • Seasonal growth driven by • Continued focus on existing geographic FLUCELVAX® and FLUAD®, markets, particularly the US supported by effectiveness data • Incremental growth through • Continued stron
Slide 14: Concluding comments
CONCLUDING COMMENTS For personal use only • Following our successful turnaround, Seqirus is well- placed to deliver further growth • We are leading the industry in the transition to next- generation, differentiated products offering enhanced effectiveness • In the near / medium term, differentiation
Slide 15: Thank you and questions
For personal use only THANK YOU AND QUESTIONS .≈ 15 | ON THE FRONT LINE
Slide 16: Key product technologies: cell-culture & MF59 adjuvant
KEY PRODUCT TECHNOLOGIES: CELL-CULTURE & MF59® ADJUVANT For personal use only MF59 Adjuvant ANTIGENIC DISTANCE CELL SEED EGG SEED CIRCULATING STRAIN ANTIGENIC DISTANCE 16 | ON THE FRONT LINE